drugset / Trial / NCT02310022

A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules

NCT02310022

Phase 1/2 Completed 48 enrolled Matinas Biopharma, Inc
RandomizedCrossoverOpen-labelTreatment

Summary

Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3 medication comparator.

Timeline

Start
2014-11
Primary completion
2015-05
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator EPA ethyl esters Unknown 4 g
Subject OMEGA-3-PENTAENOIC ACIDS Small molecule 4 g

Indications